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http:WHAT THIS PAPER ADDS
There is a general perception (with no supporting evidence) that percutaneous closure of antegrade femoral
punctures is associated with a disproportionately high rate of deployment failures, resulting in limited usage of
vascular closure devices. This paper highlights the difference between antegrade and retrograde modes of
vascular closure device deployment, and indicates that though there is indeed a higher deployment failure rate
with the Angio-Seal VIP after antegrade punctures, both deployment modes are effective, and this should not
discourage clinicians from VCD deployment after antegrade femoral punctures.Objectives: Small published series suggest a higher failure rate for Angio-Seal vascular closure device (VCD)
deployment after antegrade femoral puncture, despite the need for shorter haemostasis times, early discharge,
and possibly higher turnover. We seek to compare the deployment efﬁcacy and complications of the Angio-Seal
VCD between antegrade and retrograde femoral arterial deployments.
Methods: Radiological data was retrospectively analysed from prospective databases from the hospitals’
Computerised Radiology Information System (CRIS) over 2010e2012. Angio-Seal gauge, Rutherford class (as
applicable), puncture mode (used to classify deployment as antegrade/retrograde), sheath sizes, and deployment
success/failures were recorded. Numerical/statistical analyses were undertaken using Microsoft Excel 10/SISA
software.
Results: A total of 519 Angio-Seal VIP VCDs were deployed in 470 patients over 2010e2012 (13 other patients
could not be analysed due to incomplete data). Sheath sizes for antegrade/retrograde femoral puncture were 5F,
n ¼ 22/9; 6F, n ¼ 244/223; 7F, n ¼ 1/5; 9F, n ¼ 4/0. 8F Angio-Seal VIPs were used for 9F punctures only, 6F for
the remainder. The overall deployment success rate was 93.7%. In total, 247 (91.1%) successful antegrade
deployments were undertaken with 24 (8.9%) failures, compared with 229 (96.6%) successful retrograde
deployments with eight (3.4%) failures. Antegrade/retrograde failures were classed as failure to deploy, n ¼ 15/5;
bleeding despite successful deployment requiring supplementary compression, n ¼ 6/1; haematoma formation,
n ¼ 2/1; groin pain, n ¼ 0/1; vessel stenosis, n ¼ 1/0. Higher deployment failures were noted with antegrade
deployment (p < .02, chi-square test).
Conclusions: Angio-Seal deployment is successful for both antegrade/retrograde femoral punctures albeit with a
higher antegrade failure rate.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 5 November 2013, Accepted 15 April 2014, Available online 28 May 2014
Keywords: Angio-Seal, Vascular closure device, Femoral artery puncture, Angiography/angioplasty, HemostasisINTRODUCTION
Use of vascular closure devices (VCDs) is now part of the
standard armamentarium in achieving groin haemostasis
following femoral arterial puncture for peripheral arterial
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//dx.doi.org/10.1016/j.ejvs.2014.04.017deployment of such devices, typiﬁed here by the Angio-Seal
VIP (“V-Twist Integrated Platform”; St. Jude Medical, Min-
netonka, MN, USA). However, there are limited published
data, with heterogeneity of study parameters, comparing it
to manual compression,1e3 to other VCDs,4 or simply reg-
istries.5 There is also very limited data so far comparing the
efﬁcacy of the Angio-Seal (now used to imply the Angio-Seal
VIP throughout) VCD between retrograde and antegrade
punctures. We therefore seek to compare the deployment
efﬁcacy and complications of the Angio-Seal VCD in ante-
grade and retrograde femoral arterial punctures in a large
series.
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vascular collagen plug and an anchoring low-proﬁle intra-
vascular foot plate which is designed to dissolve in 90 days
(Fig. 1A). The anchor allows counter-traction via the thread
whilst the plug is pushed into place to cover the arterial
puncture. It is easy to use, and consists of a few simple
steps: (a) introduction of the dedicated Angio-Seal sheath
over a guidewire; (b) adjusting the sheath using the
convenient arteriotomy locator provided (blood ﬂow is
correspondingly visible on the outside), so that there is only
1.5 cm of its end that is intra-arterial (this prevents over-
insertion with its attendant risk of intra-arterial plug
deployment, or failure of anchorage); (c) removal of the
guidewire and introduction of the anchor and plug delivery
system (“carrier tube”); (d) locking the delivery system into
the sheath, with intraluminal delivery of the anchor; (e)
pullback of the entire system, that is delivery system and
sheath, so that the anchor now abuts the intimal aspect,
and tamping the collagen plug onto the femoral artery
adventitia with the dedicated tamping tube that is provided
within the system over the thread. A wait of about 60
seconds in general achieves haemostasis via an “anchore
arteriotomyecollagen plug sandwich” (Fig. 1A). The thread
is then cut ﬂush to the skin and the VCD delivery system/
sheath removed.Figure 1. (A) Schematic of the Angio-Seal VIP outlining the “anchorear
of the Angio-Seal VIP with the “carrier tube” element locked into
c ¼ protruding foot plate in line with the device prior to deployment, e
St. Jude Medical are trademarks of St. Jude Medical Inc. or related com
rights reserved).Other variants of the Angio-Seal include the newer
Angio-Seal Evolution and the older Angio-Seal STS (Self-
Tightening Suture)-Plus, both of which also come in 6F and
8F conﬁgurations. The former has an internal geared system
that automatically tamps the collagen plug down whilst the
device is being withdrawn. The Angio-Seal VIP (Fig. 1B) is
similar to the Angio-Seal STS but with a larger footprint for
the collagen plug, which is relevant to “downsizing” as
discussed below.MATERIALS AND METHODS
Data was retrospectively analysed from prospective data-
bases from the hospitals’ Computerised Radiology Infor-
mation System (CRIS) over 2010e2012. Angio-Seal gauges
were identiﬁed from procedure reports, whilst Rutherford
class (where interventions were undertaken for peripheral
arterial disease) was also identiﬁed from the report and
cross checked from the request form. Location of the
optimal puncture point was undertaken using immediate
pre/intra-procedure duplex ultrasound scan (DUS), which
also allows avoidance of anterior calciﬁcations as far as
possible; magnetic resonance angiography (MRA) is our
preferred modality for arterial imaging,6 with computed
tomographic angiography (CTA) used usually in urgent casesteriotomyecollagen plug sandwich”. (B) Indicating the appearance
the sheath (a ¼ carrier tube element; b ¼ sheath element;
xtent of elements arrowed). Used with permission (Angio-Seal and
panies. Reprinted with permission of St. Jude Medical, 2013 All
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and a DUS-only approach in those who are suitable for none
of the previous. We have no speciﬁc protocol for sizing the
artery as such and work simply on how the artery is
visualised pre- and intra-procedure.
Puncture mode (used to classify deployment as ante-
grade/retrograde) was determined from the type of pro-
cedure, as also sheath sizes and deployment success/
failures which were recorded. Failure was taken to include
(a) failure of deployment, and also (b) bleeding despite
successful deployment requiring supplementary compres-
sion, (c) haematoma formation after perceived successful
deployment, (d) groin pain, and (e) vessel stenosis.
Patients were typically asked to rest for 2 hours7 (though
we acknowledge this can be less) after successful deploy-
ment, with observations in the recovery ward, and then
discharged, with the majority of cases undertaken on a day
case basis. Groins were not reassessed immediately after-
wards using DUS as a routine.
Numerical and statistical analyses were undertaken using
Microsoft Excel 10 and SISA statistical software respectively.
Two-group two-sample non-parametric data analyses were
undertaken using chi-square tests in 2  2 table format,
modiﬁed to the Fisher exact test when a parameter fre-
quency was <5.Figure 2. Computed tomography angiography indicating stenosis
(arrowed) in the right common femoral artery.RESULTS
A total of 519 Angio-Seals were deployed in 470 patients
(305 male, 165 female) from March 2010 to October 2012.
Thirteen other patients could not be analysed due to
incomplete data. 8F Angio-Seals were used for 9F punctures
only, 6F for the rest.
Speciﬁcally there were 282 antegrade (including 11 other
deployments excluded from the comparative analysis; 7
“turnarounds” [i.e. procedures where a catheter had been
turned around from the abdominal aorta after an iliac
procedure and then redirected to the femoropopliteal
segment]; 2 double deployments in the same groin e deep
femoral (DFA)/common femoral arteries (CFAs), and CFA
twice) and 237 retrograde punctures. Closure success was
therefore compared between 271 true antegrade punctures
and 237 retrograde punctures, totalling 508 deployments
available for analysis.
Indications (designated here in terms of Angio-Seals
deployed) for antegrade punctures were mostly for femo-
ropopliteal/crural occlusive disease (n ¼ 246) and also for
popliteal endovascular aneurysm repair (n ¼ 4). This was
more diverse for the retrograde group (typically in-
terventions for iliac occlusive disease), including, for
example, subclavian angioplasty (n ¼ 1), uterine ﬁbroid
embolisation (n ¼ 3), diagnostic angiography for a hand
arteriovenous malformation (AVM; n ¼ 1), renal emboli-
sation (n ¼ 2), AV ﬁstuloplasty (n ¼ 1), pre-EVAR internal
iliac interventions (n ¼ 2), internal iliac angioplasty for
erectile dysfunction (n ¼ 2).
A total of 247 (91.1%) successful antegrade deployments
were undertaken with 24 (8.9%) failures, and 229 (96.6%)successful retrograde deployments with eight (3.4%) fail-
ures. There was a signiﬁcantly higher failure rate with
antegrade deployment (p < .02, chi-square test). This held
true when comparing pure deployment failures alone as
well (p ¼ .02, Fisher exact test).
The overall combined deployment success rate was 93.7%,
when combining both groups.When analysing the failures in
themselves, the total complication rate despite successful
deployment was 12 of 32 (37.5%), whilst true deployment
failures numbered 20 of 32 (72.5%) failures overall.
All patients with failed deployments and bleeding com-
plications were observed overnight, counselled for bruising
and possible need for further intervention; they needed no
further intervention and were problem-free at routine
follow-up at the vascular surgical outpatient clinic. Simple
failure to deploy with no bleeding complications was suc-
cessfully managed with manual pressure. The patient with
groin pain was managed conservatively with adequate
symptom relief. One patient presenting with femoral arte-
rial stenosis manifested as recurrent right leg claudication at
about 8 weeks; CTA indicated a stenosis at the puncture site
(Fig. 2), which was corroborated at open femoral artery
exploration as due to a ﬁbrotic nodule arising from the
intima (specimen not examined histologically). The common
femoral artery was endarterectomised and closed with a
prosthetic patch, with symptom resolution.
These results are summarised in Table 1.
DISCUSSION
Use of the Angio-Seal VIP is widespread in interventional
radiology and interventional cardiology, with beneﬁts





Patients 286 175 9
Gender (M/F) 175/91 121/54 7/2
Mean age (SD) 73.1 (11.3) 66.7 (12.3) 66.0 (12.3)
Rutherford class
2 7 1 0
3 109 168 6
4 5 20 1
5 90 17 0
6 35 1 0
Unrecorded 22 10 2
NA 3 20 0
Sheath sizes
5 22 9 0
6 244 223 11
7 1 5 0
8 0 0 0
9 4 0 0
Deployed numbers
Total number 271 237 11
Angio-Seal size
6F 267 237 11
8F 4 0 0
Haemostasis
Success (%) 247 (91.1) 229 (96.6) 11
Failure (%) 24 (8.9) 8 (3.4) 0
Failure speciﬁcs (%)
Failed to deploy 15 (5.5) 5 (2.2) 0
Bleeding 6 (2.2) 1 (0.4) 0
Haematoma 2 (0.73) 1 (0.4) 0
Groin pain 0 1 (0.4) 0
Vessel stenosis 1 (0.37) 0 0
NA ¼ not applicable.
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is primarily aimed for punctures smaller than 8F, given that
is manufactured in 6F and 8F conﬁgurations, and is ideally
deployed in vessels >5 mm in diameter.7 However, given
the size of the plug, it is possible to downsize for larger
holes, as is our experience.9 In fact, recently, synchronous
dual deployments in single large calibre arterial defects
employing a “double-Angio-Seal” technique have also been
described.10 As per the Instructions for Use, there are no
contraindications as such, especially relating to antegrade
punctures.
Possible adverse effects as described by the manufac-
turers include bleeding or haematoma, AV ﬁstula or pseu-
doaneurysm, infection, allergic reaction, foreign body
reaction, inﬂammation, or oedema. The last one may be
responsible for groin pain and vessel stenosis, as noted in
our series. However, inappropriate deployment has been
associated with ischaemic problems, from intra-arterial plug
deployment,11 embolisation,12 to delayed occlusive-
ischaemic complications that often necessitate open surgi-
cal reconstruction at the common femoral bifurcation.13
The incidence of complications does not seem to havechanged with emerging generations of devices, with a
reassuringly high success rate in terms of deployment.14,15
Correspondingly, we do not feel there is a need to under-
take immediate post-procedure DUS, which is reﬂective of
real-world practice; this is not what centres undertake, and
would unnecessarily add to the turnover time in our view,
which is precisely what we seek to reduce.6,7 In general,
given the known efﬁcacy and early time to hemostasis as
indicated in the IFU (100% hemostasis by 10 minutes using
both the 6F and 8F devices),7 as also early ambulation
times, post-procedure DUS may be counter-productive and
probably only pick up insigniﬁcant haematomas that would
occur as a default of the puncture, whereas it is our view
that larger ones would be clearly clinically apparent within
the 2-hour observation period, which is well within the
timeframe described even in older, more conservative
papers.7
Strategies, though, are required to deal with failed de-
ployments such as those noted in this series. Failed de-
ployments without active bleeding can be simply managed
by manual pressure alone, much as when no VCD is used,
with an extended period of post-procedure observation, as
outlined. Failed deployments with bleeding complications
may require prolonged pressure (thereby also requiring a
protracted period of observation, including admission), and
even use of adjuncts such as the FemStop (RADI Medical
Systems, Uppsala, Sweden) or haemostatic pads such as the
QuikClot Interventional Hemostatic Bandage (Z-Medica
Corporation,Wallingford, CT, USA); we did not need these in
this series. Patients should be counselled regarding the
expected bruising in the genitofemoral region, the need for
further investigations including DUS and CTA, and also
further interventions including surgery. It would also be
prudent in our view to check clotting parameters such as
activated partial thromboplastin time (APTT) in those with
prolonged bleeding despite successful deployment, and in
cases of patients who are hyper-responsive to heparin.
Abnormally high APTT levels can be successfully reversed
with protamine. Groin pain may respond to simple analgesic
measures or may need a referral to a chronic pain specialist.
Post-deployment anatomical problems such as the CFA
stenosis noted will of course need appropriate surgical
reconstruction.
There is a paucity of Level 1 evidence regarding the ef-
ﬁcacy and safety of the Angio-Seal VIP, though small trials
have looked at the other Angio-Seal versions.16 Our study,
though observational, is one of the largest so far, particu-
larly in the context of retrograde versus antegrade com-
parisons. There is also a perception amongst some
interventionists (who then resort to manual compression to
achieve haemostasis) that antegrade deployments fail
regularly, despite the need for shorter haemostasis times,
early discharge and possibly higher turnover; we feel the
results presented here effectively dispel that myth.
For the purpose of the study we have included both
technical and non-technical complications under the “de-
vice failure” umbrella, as this is the true reﬂection of the
efﬁcacy of the device. Our total success rate of 93.7%, as
224 A. Chaudhuri et al.per the criteria we have employed, is therefore slightly
lower than the 96e97% success rates quoted in the liter-
ature which, however, only measures the technical
deployment success rate.1,5,17,18 Sub-analysis of our tech-
nical deployment success (96.1%, including all successful
deployments) matches published rates, though. Complica-
tions described in the literature but not encountered in our
series include vessel occlusion/thrombosis, groin haema-
toma requiring transfusion, retroperitoneal haematoma,
pseudoaneurysm formation, AV ﬁstula, plug embolisation,
distal ischaemia, and infection.1e5,19e22
This study indicates that the Angio-Seal is effective, with
a high deployment success rate matching that in the liter-
ature. There is a signiﬁcantly higher device failure with
antegrade punctures, which correlates to published ﬁg-
ures.5 Our series has shown an overall low complication
rate, comprising only minor complications, thus supporting
the concept Angio-Seal is a safe VCD. In our hands, concern
about the turnaround technique may also be allayed: in
such cases, ﬂush angiography is undertaken with a 4F
catheter, and the turnaround undertaken using a Side-
winder catheter with its tip pointing caudally. This does not
increase the arteriotomy size till a 6F sheath is then intro-
duced as per standard for the antegrade procedure, which
can be conveniently closed with a 6F Angio-Seal, and as is
the case with this series, there were no failed deployments
in this scenario.
The signiﬁcant difference between antegrade and retro-
grade deployment rates is probably multifactorial, and not
addressing all such factors may be a limitation of this study,
which we have tried to address. So far, only obesity has
been reported as an independent risk factor for deployment
failure in antegrade punctures.22 In contrast though, other
papers examining this issue in the context of percutaneous
EVAR have suggested that BMI is not relevant to VCD
deployment success rates, though of course punctures in
such cases are by default retrograde.23 It is certainly our
experience that traversing through a fatty/deep groin in an
antegrade fashion can create a right angle kinking the
Angio-Seal sheath, which may contribute to deployment
difﬁculty and failure. However, BMI was not speciﬁcally
included as a parameter within this study, and is a possible
limitation. Similarly, we lack long-term follow-up, but, again,
this is a reﬂection of real-world practice with such cases.
Angio-Seal deployment is recorded routinely in all proce-
dural reports, which eliminates recall bias. Antiplatelet
agents were not stopped in any of the patients, and an-
gioplasties were not undertaken if the patients’ INR
exceeded 1.5. Furthermore, whilst the puncture method
may be an issue, the fact that a VCD is being used negates
whether the puncture was US guided (as is our practice) or
ﬂuoroscopy guided using the femoral head, as these aspects
are no longer relevant to achievement of haemostasis with
successful deployment.
In conclusion, this large series suggests that Angio-Seal
VIP deployment is successful for both antegrade/retro-
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